Skip to content

Trial · Interventional

Active, not recruitingPhase 3Registry data

A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight

Short name TRIUMPH-8

NCTNCT07232719 (opens ClinicalTrials.gov in a new tab)Other id27769Other idJ1I-MC-GZQJ
Open at ClinicalTrials.govAsk about this trial

Overview

Status
Active, not recruiting
Phase
Phase 3
Enrollment
250 participants (estimated)
Sponsor
Eli Lilly and Company · Industry
Design
Randomized · Double masking
Countries
2 countries

United States, United Kingdom

Start
17 Nov 2025
Primary completion
Jul 2027 (estimated)
Completion
Jul 2027 (estimated)
First posted
18 Nov 2025
Last update posted
17 Apr 2026
Conditions
Obesity · Overweight

Timeline

1 trial · 1 ongoing

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
2025202620272028
  1. Ph 3

    TRIUMPH-8

    NCT07232719

    17 Nov 2025 to est. Jul 2027

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

The purpose of this study is to evaluate the efficacy and safety of retatrutide compared with placebo for body weight reduction. Participation in the study will last about 65 weeks and may include about 18 visits.

Interventions

  • RetatrutideDrug
  • PlaceboDrug

Arms3

  • Experimental

    Retatrutide Dose 1

    Participants will receive retatrutide subcutaneously (SC)

  • Experimental

    Retatrutide Dose 2

    Participants will receive retatrutide SC

  • Placebo comparator

    Placebo

    Participants will receive placebo SC

Primary outcomes1

Outcomes the sponsor listed as primary.

  1. Percent Change from Baseline in Body Weight

    Time frame · Baseline, Week 56

Secondary outcomes(4)

  1. Change from Baseline in Systolic Blood Pressure

    Time frame · Baseline, Week 56

  2. Change from Baseline in Waist Circumference

    Time frame · Baseline, Week 56

  3. Percent Change from Baseline in Non-High-Density Lipoprotein (HDL) Cholesterol

    Time frame · Baseline, Week 56

  4. Pharmacokinetics (PK): Steady State Area Under the Concentration Time Curve (AUC)

    Time frame · Baseline through Week 56

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

A trial that is still running, or that stopped early, may post results later.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies0

Studies that cite this trial.

No study cites this trial.

Eligibility

Who could join, as posted.

Sex
All
Age
from 18 Years
Healthy volunteers
Not accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * Have a body mass index (BMI) of: * ≥30 kilogram per square meter (kg/m2) OR * ≥27 kg/m2 with at least one of the following weight-related conditions: high blood pressure, abnormal levels of lipid, obstructive sleep apnea, heart disease * Have at least one unsuccessful attempt to lose weight by dieting Exclusion Criteria: * Have a self-reported change in body weight \>5 kg (11 pounds) within 90 days before screening * Have a prior or planned surgical treatment for obesity * Have type 1 diabetes or type 2 diabetes * Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2) * Have had within the past 90 days before screening * acute myocardial infarction * cerebrovascular accident (stroke) * hospitalization for unstable angina, or * hospitalization due to congestive heart failure * Have New York Heart Association Functional Classification Class IV congestive heart failure * Have a history of chronic or acute pancreatitis * Have taken weight loss drugs, including over-the counter medications within 90 days prior to screening

PepBank is a research reference. Talk to a doctor before you use any peptide.